Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01<sub>E-4</sub> tuberculosis vaccine.

Dagnew AF, Noble R, Cinar A, Burhan E, Churchyard G, Fairlie L, Hanekom WA, Muyoyeta M, Mwandumba HC, Nduba V, Curran M, Schmidt AC.

Open source

DOI
10.1016/j.vaccine.2026.128690
Published
2026-05-12
Container
Vaccine
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.vaccine.2026.128690,
  title = {Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01\<sub\>E-4\</sub\> tuberculosis vaccine.},
  author = {Dagnew AF and  Noble R and  Cinar A and  Burhan E and  Churchyard G and  Fairlie L and  Hanekom WA and  Muyoyeta M and  Mwandumba HC and  Nduba V and  Curran M and  Schmidt AC.},
  year = {2026},
  journal = {Vaccine},
  doi = {10.1016/j.vaccine.2026.128690},
  url = {https://doi.org/10.1016/j.vaccine.2026.128690}
}

RIS

TY  - JOUR
TI  - Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01<sub>E-4</sub> tuberculosis vaccine.
AU  - Dagnew AF
AU  -  Noble R
AU  -  Cinar A
AU  -  Burhan E
AU  -  Churchyard G
AU  -  Fairlie L
AU  -  Hanekom WA
AU  -  Muyoyeta M
AU  -  Mwandumba HC
AU  -  Nduba V
AU  -  Curran M
AU  -  Schmidt AC.
PY  - 2026
JO  - Vaccine
DO  - 10.1016/j.vaccine.2026.128690
UR  - https://doi.org/10.1016/j.vaccine.2026.128690
ER  - 

APA

AF, D., R, N., A, C., E, B., G, C., L, F., WA, H., M, M., HC, M., V, N., M, C., & AC., S. (2026). Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01<sub>E-4</sub> tuberculosis vaccine.. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128690

Source records